Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study

Abstract

Background

Improved prognosis in women with multiple sclerosis (MS) undergoing immunosuppressive treatment with mitoxantrone (MITO) has led to an increased interest in the effect of such treatments on fertility. FErtility and Mitoxantrone In MS (FEMIMS) is a collaborative retrospective study aimed at evaluating the impact of MITO treatment on fertility in women with MS.

Methods

Occurrence of chemotherapy-induced amenorrhea (CIA) was evaluated in 189 women with MS treated with MITO before the age of 45. An “ad hoc” questionnaire, paying particular attention to onset of CIA either during or post-MITO treatment, was administered to each patient. The probability of CIA was calculated using a multivariate logistic regression analysis taking into account age at exposure, cumulative dose, and use of estroprogestinic (EP) drugs during treatment.

Results

Forty-eight (26%) patients presented CIA following MITO. The probability of CIA was increased by 2%/mg/m² of cumulative dose and by 18% for each year of age, whereas it was reduced by administration of EP during treatment.

Conclusions

MITO treatment may affect reproductive capacity in women with MS. Patients of childbearing age should be properly counseled before MITO treatment and EP therapy should be administered to reduce the risk of CIA.

Keywords

amenorrhea estroprogestinic drug fertility immunosuppressive drugs mitoxantrone multiple sclerosis

Get full access to this article

View all access options for this article.

References

1 Ferrero S Pretta S Ragni N . Multiple sclerosis: management issue during pregnancy. Eur J Obstet Gynecol Reprod Biol 2004; 115: 3–9.

2 Cavalla P Rovei V Masera S . Fertility in patients with multiple sclerosis: current knowledge and future perspectives. Neurol Sci 2006; 27: 231–239.

3 Tintoré M . Early MS treatment. Int MS J 2007; 14: 5–10.

4 Cocco E Marchi P Sardu C . Mitoxantrone treatment in patients with early relapsing–remitting multiple sclerosis. Mult Scler 2007; 13: 975–980.

5 Le Page E Leray E Taurin G . Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5-year follow-up observational study of 100 consecutive patients. J Neurol Neurosurg Psychiatry 2007; 79: 52–56.

6 Rieckmann P Toyka KV Bassetti C . Escalating immunotherapy of multiple sclerosis – new aspects and practical application. J Neurol 2004; 251: 1329–1339.

8 Gonsette RE . Compared benefit of approved and experimental immunosuppressive therapeutic approaches in multiple sclerosis. Expert Opin Pharmacother 2007; 8: 1103–1116.

9 Ostensen M Khamashta M Lockshin M . Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther 2006; 8: 209.

10.

10 Rivera V; Houston TX; Al-Sabbagh A; . Ongoing evaluation of the safety and tolerability of Mitoxantrone in worsening multiple sclerosis: the RENEW study. Neurology 2007; P06.080 [abstract].

11.

11 Kerr JA; Eisenberg E; Sadiq SA; . Mitoxantrone therapy-associated menstrual dysfunction in patients with multiple sclerosis. Neurology 2007; P06.081 [abstract].

12.

12 McDonald WI Compston A Edan G . Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121–127.

13.

13 Polman C Reingold SC Edan G . Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 2005; 58: 840–846.

14.

14 Yen SSC Jaffe RB Barbieri RL . Reproductive endocrinology. 4th ed. Philadelphia: W.B. Saunders Company; 1999. p. 480.

15.

15 Clemons M Simmons C . Identifying menopause in breast cancer patients: considerations and implications. Breast Cancer Res Treat 2007; 104: 115–120.

16.

16 Selvin S . Statistical analysis of epidemiological data. 2nd ed. Oxford: Oxford University Press; 1996.

17.

17 Campbell MJ . Statistics at square two. 2nd ed. London: BMJ Books; 2006.

18.

18 Norusis MJ . SPSS Advanced Statistics SPSS 6.1. Chicago: SPSS Inc; 1994.

19.

19 Lee SJ Schover LR Partridge AH . American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006; 24: 2917–2931.

20.

20 Wallace WHB Anderson RA Irvine DS . Fertility preservation for young patients with cancer: who is at risk and what can be offered. Lancet Oncol 2005; 6: 209–218.

21.

21 Fornier MN Modi S Panageas KS Norton L Hudis C . Incidence of chemotherapy induced, long term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer 2005; 104: 1575–1579.

22.

22 Walshe JM Denduluri N Swain SM . Amenorrhea in premenopausal woman after adjuvant chemotherapy for breast cancer. J Clin Oncol 2006; 24: 5769–5779.

23.

23 Meirow D Lewis H Nugent D Epstein M . Subclinical depletion of primordial follicular reserve in mice treated with cyclophosphamide: clinical importance and proposed accurate investigative tool. Hum Reprod 1999; 14: 1903–1907.

24.

24 Blumenfeld Z Dann E Avivi I Epelbaum R Rowe JM . Fertility after treatment for Hodgkin’s disease. Ann Oncol 2002; 13: 138–147.

25.

25 Lutchman Singh K Davies M Chatterjee R . Fertility in female cancer survivors: pathophysiology, preservation and the role of ovarian reserve testing. Hum Reprod Update 2005; 11: 69–89.

26.

26 Sobrinho LG Levine RA DeConti RC . Amenorrhea in patients with Hodgkin's disease treated with antineoplastic agents. Am J Obstet Gynecol 1971; 109: 135–139.

27.

27 Di Cosimo S Alimonti A Ferretti G . Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer. Ann Oncol 2004; 15: 1065–1071.

28.

28 Chasle S How CC . The effect of cytotoxic chemotherapy on female fertility. Eur J Oncol Nurs 2003; 7: 91–98.

29.

29 Minton SE Munster PN . Chemotherapy induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer. Cancer Control 2002; 9: 466–472.

30.

30 Bath LE Tydeman G Critchley HO Anderson RA Baird DT Wallace WH . Spontaneous conception in a young woman who had ovarian cortical tissue cryopreserved before chemotherapy and radiotherapy for a Ewing‘s sarcoma of the pelvis. Human Reprod 2004; 19: 2569–2572.